Close Menu

mergers & acquisitions

The $375 million deal marks the integration of Myriad, a leader in the hereditary cancer genetic screening market, with Counsyl, a leader in reproductive genetic screening.

Myriad will merge Counsyl’s reproductive tests with its preventive care business unit into a new business unit called Myriad Women’s Health.

In a note to investors, Cowen analyst Doug Schenkel called the decision "odd," and wondered if there would be more to come.

The company said its product revenues for the year rose 101 percent while its services revenues rose 7 percent.

TGR's proprietary protein capturing technology is expected to complement Sygnis' range of immunology, genomic, and proteomic products and services.

Agilent said the acquisition will enable it to provide consumers with a single informatics solution across laboratory and operational domains.

The offer put a value of 181 pence per share on Horizon's stock, representing a premium of approximately 26 percent to Horizon's closing share price on May 1.

The deal marks the latest in a series of acquisition LGC has made in recent years to expand its presence on the nucleic acid chemistry market.

Upon completion of the transaction, Rosetta will become a privately held subsidiary of Genoptix and its shares will cease to trade on the Nasdaq.

The firm is selling BioServe to Reprocell as part of Cancer Genetics' transformation and strategic plan to bring itself to profitability.

Pages

Bloomberg reports that the DNA-for-cash deal reported in Kentucky might be a more widespread scam.

St. Jude Children's Research Hospital scientists have treated infants with X-linked severe combined immunodeficiency using gene therapy in an early phase study.

St. Louis Public Radio reports that some African Americans are turning to DNA ancestry testing to help guide genealogical searches.

In Nature this week: a genomic analysis of the snailfish Pseudoliparis swirei, ancient DNA analysis gives insight into the introduction of farming to England, and more.